InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,230.00
(
-0.15%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,254.13
(
0.26%
)
Post# of 13959
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Investor100

Send PM Follow Ignore
Followers 505
Posts 6242
Boards Moderated 0
Alias Born 09/20/2006

Investor100

Re: Investor100 post# 376

Monday, 06/20/2016 9:29:53 AM

Monday, June 20, 2016 9:29:53 AM

Post# of 13959
Immune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016

https://finance.yahoo.com/news/immune-pharmaceuticals-present-jmp-securities-120600041.html

Dr. Daniel Teper, CEO of Immune, will provide an overview of the Company's business and 2016-17 expected milestones, including updates on:

- The advancement of the two Phase 2 clinical trials in bullous pemphigoid, and orphan auto-immune skin disease, and in ulcerative colitis with bertilimumab, a fully human monoclonal antibody targeting eotaxin-1, a key regulator of immuno-inflammation and,

- The company's immuno-oncology pipeline with a focus on new data and strategy for Ceplene®, a type of immune check-point inhibitor in development in combination with low dose SC Proleukin® for the maintenance of remission in patients with Acute Myeloid Leukemia.

The presentation will be webcast and available on our website (www.immunepharma.com) after the conference.

Investor 100
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up